JP5312027B2 - 病気の治療法 - Google Patents
病気の治療法 Download PDFInfo
- Publication number
- JP5312027B2 JP5312027B2 JP2008529187A JP2008529187A JP5312027B2 JP 5312027 B2 JP5312027 B2 JP 5312027B2 JP 2008529187 A JP2008529187 A JP 2008529187A JP 2008529187 A JP2008529187 A JP 2008529187A JP 5312027 B2 JP5312027 B2 JP 5312027B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- oxybutynin
- pilocarpine
- administration
- tolterodine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Percussion Or Vibration Massage (AREA)
Description
本出願は、2005年9月2日にMehdi Paborjiにより「病気の治療法」と題して出願された米国仮出願番号60/714,150の優先権を主張し、本明細書でその全体を参照して援用するものである。
即効性のオキシブチニン、トルテロジン、ソリフェナシン、ダリフェナシン、トロスピウム、またはフェソテロジン、(以上、ピロカルピン及びテガセロドと併用)、
放出遅延型(徐放性または長時間放出型に関わりなく)のオキシブチニン、及び放出遅延型(徐放性または長時間放出型に関わりなく)のピロカルピン、
放出遅延型(徐放性または長時間放出型に関わりなく)のオキシブチニン、放出遅延型(徐放性または長時間放出型に関わりなく)のピロカルピン、及び徐放性テガセロド、
即効性のオキシブチニン、トルテロジン、ソリフェナシン、ダリフェナシン、トロスピウム、またはフェソテロジン、及びピロカルピンとテガセロドからなる放出遅延(徐放性または長時間放出に関わりなく)製剤、
放出遅延型(徐放性または長時間放出型に関わりなく)のオキシブチニン、トルテロジン、ソリフェナシン、ダリフェナシン、トロスピウム、またはフェソテロジン、及びピロカルピンと徐放性テガセロドからなる放出遅延(徐放性または長時間放出に関わりなく)製剤、
放出遅延型(徐放性または長時間放出型に関わりなく)のオキシブチニン、トルテロジン、ソリフェナシン、ダリフェナシン、トロスピウム、またはフェソテロジンと、ピロカルピンからなる放出遅延(徐放性または長時間放出に関わりなく)製剤及びテガセロドからなる即効性製剤。
本明細書記載の抗ムスカリン剤または抗コリン剤、及び本明細書記載の唾液腺の刺激を引き起こす化合物、
本明細書記載の抗ムスカリン剤または抗コリン剤、及び本明細書記載の便秘を緩和させる化合物、または
本明細書記載の抗ムスカリン剤または抗コリン剤、本明細書記載の唾液腺の刺激を引き起こす化合物、及び本明細書記載の便秘を緩和させる化合物と、
生理的に許容可能な担体、希釈剤、または賦形剤、あるいはそれらの混合物との組み合わせを含む医薬組成物に関する。
以下の実施例は、限定するものではなく、本発明の様々な態様の代表に過ぎない。
実施例1: 過活動膀胱を患う個人を治療するためのOAB薬剤と唾液腺刺激剤との組み合わせ
過活動膀胱を患う個人を同定する。この個人には、1日当たり2回のテガセロド2mgに加えて、1日当たり2回から4回、オキシブチニン5mgが投与される。この個人が、便秘について不満を訴え続ける場合、1日当たり2回のテガセロドの用量を6mgまで増量する。必要に応じて、この用量は、12mg、20mg、または50mgまで増量することができる。また、オキシブチニンの用量は、10、15、20、または30mgまで増量することができる。
オキシブチニンとピロカルピンの効果を評価するために、それら単体で、及びプラセボとの比較と組み合わせて、健康な被験者での唾液分泌に関して試験を行った。この試験の目的は、オキシブチニンとピロカルピンを経口投与した後に、唾液の流量と口渇の程度とを、それら単体で、及びプラセボとの比較と組み合わせて測定し、尿量/排尿量、及びバイタルサインに及ぼすオキシブチニンとピロカルピンの効果を、それら単体で、及びプラセボとの比較と組み合わせて判断することである。
● オキシブチニン(5mg)投与30分後にプラセボ
● ピロカルピン(5mg)投与30分後にプラセボ
● プラセボ投与30分後にプラセボ
● オキシブチニン(5mg)投与30分後にピロカルピン(5mg)
○ パラフィルムを2分間噛むことによって、唾液流量を測定する。
○ VASによって口渇度を測定する。
○ 投与後、6時間にわたり尿量/排尿量、及び尿頻度を測定する。
○ 血液サンプルを、投与前、及び投与後の0.5、1、2、3、4、及び6時間経過時点で薬物動態用に採取する。
○ 食事と水分の摂取は、6時間にわたり共通とする。
● 健康な被験者
● 12名の被験者
● 18歳以上の男性、または非妊娠女性
● 体重指数BMIが18〜28
● 抗ムスカリン剤に対する既知のアレルギーがないこと
● 緑内障、尿閉、不整脈の既往歴がないこと
● 試験登録日前の10日以内、及び試験期間を通してOTC製剤、栄養補助食品、及びビタミンを摂取しないこと
(1) 刺激時唾液流量
(2) 口渇(VAS)
(3) 投与後6時間にわたる尿量/排尿量
(4) オキシブチニンとピロカルピンの薬物動態
この試験では、オキシブチニン、ピロカルピン、この2つの組み合わせ、およびプラセボの効果を、1名の個人に対して、6回の個別であるが同一の試験で測定した。
この試験では、オキシブチニン、セビメリン、これら2つの組み合わせ、及びプラセボの効果を、個別の試験において1名の個人で測定した。
この試験では、トルテロジン、ピロカルピン、これら2つの組み合わせ、及びプラセボの効果を、個別であるが同一の試験において1名の個人で測定した。
Claims (9)
- 治療効果がある量の第1の化合物と、治療効果がある量の第2の化合物とを含む過活動膀胱治療用医薬組成物であって、前記第1の化合物は抗ムスカリン剤であり、前記第2の化合物は唾液腺の刺激を引き起こすものであり、
(1)前記第1の化合物はオキシブチニン若しくはその薬剤として許容可能な塩であり且つ前記第2の化合物はピロカルピン若しくはその薬剤として許容可能な塩であるか、又は、
(2)前記第1の化合物はトルテロジン若しくはその薬剤として許容可能な塩であり且つ前記第2の化合物はピロカルピン若しくはその薬剤として許容可能な塩である
医薬組成物。 - 前記第1の化合物と前記第2の化合物とが、前記第2の化合物による最大唾液流量発生時点が前記第1の化合物による最小唾液流量発生時点とほぼ同時に生じるように製剤されている請求項1に記載の組成物。
- 薬剤として許容可能な担体、希釈剤、又は賦形剤を更に含んでいる請求項1又は2に記載の組成物。
- 前記ピロカルピンは前記トルテロジンが放出されてから22〜30分の間に放出されるか、又は、前記ピロカルピンは前記オキシブチニンが放出されてから30〜60分の間に放出される請求項2に記載の組成物。
- 前記第1の化合物が1mg〜30mgの用量で存在している請求項1乃至3の何れか1項に記載の組成物。
- 前記第2の化合物が1mg〜30mgの用量で存在している請求項1乃至3の何れか1項に記載の組成物。
- 前記オキシブチニンが5mg又は10mgの用量で存在し、前記トルテロジンは1mg又は2mgの用量で存在している請求項1に記載の組成物。
- 前記ピロカルピンが5mg又は10mgの用量で存在している請求項1に記載の組成物。
- 請求項1乃至8の何れかに記載の組成物の、過活動膀胱治療用薬剤の製造のための使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71415005P | 2005-09-02 | 2005-09-02 | |
US60/714,150 | 2005-09-02 | ||
PCT/US2006/033671 WO2007027675A1 (en) | 2005-09-02 | 2006-08-28 | Therapy for the treatment of disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009507021A JP2009507021A (ja) | 2009-02-19 |
JP5312027B2 true JP5312027B2 (ja) | 2013-10-09 |
Family
ID=37502599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008529187A Expired - Fee Related JP5312027B2 (ja) | 2005-09-02 | 2006-08-28 | 病気の治療法 |
Country Status (19)
Country | Link |
---|---|
US (6) | US7678821B2 (ja) |
EP (1) | EP1933833B8 (ja) |
JP (1) | JP5312027B2 (ja) |
KR (1) | KR101054248B1 (ja) |
CN (2) | CN101287462A (ja) |
AT (1) | ATE506059T1 (ja) |
AU (1) | AU2006284940B2 (ja) |
BR (1) | BRPI0615432A2 (ja) |
CA (1) | CA2619565C (ja) |
DE (1) | DE602006021444D1 (ja) |
DK (1) | DK1933833T3 (ja) |
ES (1) | ES2365161T3 (ja) |
IL (1) | IL189546A (ja) |
NZ (1) | NZ565840A (ja) |
PL (1) | PL1933833T3 (ja) |
PT (1) | PT1933833E (ja) |
RU (1) | RU2435610C2 (ja) |
WO (1) | WO2007027675A1 (ja) |
ZA (1) | ZA200802811B (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101054248B1 (ko) * | 2005-09-02 | 2011-08-08 | 테라비다, 인코포레이티드 | 질환 치료용 요법 |
JP5637551B2 (ja) * | 2005-12-28 | 2014-12-10 | キッセイ薬品工業株式会社 | 唾液腺障害の治療用医薬 |
US20100297225A1 (en) * | 2007-12-20 | 2010-11-25 | Pharmathen S.A. | Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
EP3646870A1 (en) | 2009-07-22 | 2020-05-06 | Puretech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
SG174658A1 (en) * | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
WO2011123815A1 (en) * | 2010-04-01 | 2011-10-06 | Theravida, Inc. | Methods of improving quality of sleep |
CN102325467B (zh) * | 2010-05-12 | 2013-10-09 | 沈宝美 | 根据体质不同的用于改善便秘的天然食品组合物 |
AR088410A1 (es) * | 2010-06-22 | 2014-06-11 | Teva Womens Health Inc | Dispositivos intravaginales que comprenden agentes anticolinergicos y metodos para prepararlos |
US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
KR101932714B1 (ko) * | 2010-09-28 | 2018-12-26 | 삼성전자주식회사 | 소셜 그룹 생성 및 연결 방법, 그 방법을 수행할 수 있는 유저 디바이스, 서버 및 저장 매체 |
US20120289561A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder |
US20120289564A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder |
US20120289560A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
WO2012154892A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of propiverine and salivary stimulants for the treatment of overactive bladder |
WO2012154778A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder |
WO2012154775A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder |
KR20140044816A (ko) * | 2011-05-10 | 2014-04-15 | 테라비다, 인코포레이티드 | 과민성 방광을 치료하기 위한 솔리페나신과 타액 자극제의 복합제 |
AU2012253669A1 (en) * | 2011-05-10 | 2013-11-28 | Theravida, Inc. | Combinations of trospium and salivary stimulants for the treatment of overactive bladder |
AU2013235518B2 (en) * | 2012-03-19 | 2017-03-02 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
EP2844239A1 (en) | 2012-05-01 | 2015-03-11 | TheraVida, Inc. | Methods for the treatment of overactive bladder |
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
WO2016106182A1 (en) * | 2014-12-23 | 2016-06-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot |
EP3265128A4 (en) | 2015-03-06 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system muscarinic agonist combination |
JP6841834B2 (ja) | 2016-01-20 | 2021-03-10 | テラヴィダ, インコーポレイテッドTheraVida, Inc. | 多汗症の処置のための方法および組成物 |
HUE058931T2 (hu) | 2018-04-24 | 2022-09-28 | Allergan Inc | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére |
NZ773719A (en) | 2018-09-28 | 2022-07-29 | Karuna Therapeutics Inc | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
EP3967311A1 (en) | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
US11564909B2 (en) | 2020-11-30 | 2023-01-31 | Romeg Therapeutics Llc | Methods and compositions for oral pilocarpine liquid |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
EP2266564B1 (en) | 1997-12-22 | 2013-03-13 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist |
WO1999032120A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
US6482837B1 (en) | 1998-04-24 | 2002-11-19 | University Of Rochester | Antimuscarinic compounds and methods for treatment of bladder diseases |
WO2001054728A1 (en) * | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
WO2006132196A1 (ja) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β3作動薬を含有する新規な医薬 |
KR101054248B1 (ko) * | 2005-09-02 | 2011-08-08 | 테라비다, 인코포레이티드 | 질환 치료용 요법 |
-
2006
- 2006-08-28 KR KR1020087005797A patent/KR101054248B1/ko active IP Right Grant
- 2006-08-28 EP EP06813885A patent/EP1933833B8/en not_active Not-in-force
- 2006-08-28 DE DE602006021444T patent/DE602006021444D1/de active Active
- 2006-08-28 PT PT06813885T patent/PT1933833E/pt unknown
- 2006-08-28 DK DK06813885.8T patent/DK1933833T3/da active
- 2006-08-28 CN CNA2006800320978A patent/CN101287462A/zh active Pending
- 2006-08-28 US US11/467,760 patent/US7678821B2/en active Active
- 2006-08-28 AU AU2006284940A patent/AU2006284940B2/en active Active
- 2006-08-28 CN CN2013100336427A patent/CN103142586A/zh active Pending
- 2006-08-28 AT AT06813885T patent/ATE506059T1/de active
- 2006-08-28 RU RU2008112687/15A patent/RU2435610C2/ru not_active IP Right Cessation
- 2006-08-28 WO PCT/US2006/033671 patent/WO2007027675A1/en active Application Filing
- 2006-08-28 PL PL06813885T patent/PL1933833T3/pl unknown
- 2006-08-28 CA CA2619565A patent/CA2619565C/en active Active
- 2006-08-28 ES ES06813885T patent/ES2365161T3/es active Active
- 2006-08-28 NZ NZ565840A patent/NZ565840A/en not_active IP Right Cessation
- 2006-08-28 ZA ZA200802811A patent/ZA200802811B/xx unknown
- 2006-08-28 BR BRPI0615432-8A patent/BRPI0615432A2/pt not_active IP Right Cessation
- 2006-08-28 JP JP2008529187A patent/JP5312027B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-14 IL IL189546A patent/IL189546A/en not_active IP Right Cessation
-
2009
- 2009-07-15 US US12/503,432 patent/US20090275629A1/en not_active Abandoned
- 2009-09-08 US US12/555,806 patent/US7666894B2/en active Active
-
2010
- 2010-02-22 US US12/710,301 patent/US8470864B2/en active Active
- 2010-02-22 US US12/710,310 patent/US7781472B2/en not_active Expired - Fee Related
-
2013
- 2013-06-24 US US13/925,220 patent/US20130289087A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5312027B2 (ja) | 病気の治療法 | |
MX2012011395A (es) | Metodos de mejoramiento de la calidad del sueño. | |
JP6499634B2 (ja) | 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ | |
MX2013013124A (es) | Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva. | |
MX2008002907A (es) | Terapia para tratamiento de enfermedad | |
NZ617375B2 (en) | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder | |
WO2012154771A1 (en) | Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120423 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120501 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120524 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120622 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130223 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130304 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130325 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130424 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130702 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5312027 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |